Acute leukaemia Flashcards

1
Q

What is acute leukaemia?

A

Result of accumulation of early myeloid or lymphoid precursors in the bone marrow, blood and other tissues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How does acute leukaemia arise?

A
  • Probably occurs by somatic mutation in a single cell within a population of early progenitor cells
  • May arise de novo or be the terminal event of a pre-existing blood disorder
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the two main subgroups of acute leukaemia?

A
  • Acute myeloid leukaemia (AML)

- Acute lymphoblastic leukaemia (ALL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What criteria is used to further divide acute leukaemia in various subcategories?

A

Morphological

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the clinical features of acute leukaemia?

A
  • Presents with features of bone marrow failure: anaemia, infections, easy bruising and haemorrhage
  • Organ infiltration by leukaemia cells may occur e.g. spleen, liver, meninges, testes and skin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the two different ways of classifying AML?

A
  • FAB classification – ‘morphological’

- WHO classification – ‘risk adapted’

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What molecular technique lies at the cornerstone of leukaemia diagnosis?

A
  • Monoclonal antibody determination of surface antigen expression
  • Immunoflouresence and particularly flouresence activated cell sorting (FACS) allows rapid leukaemia diagnosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How might cytogenetic analysis be useful?

A

May help confirm the diagnosis and indicate subtype

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the Philadelphia chromosome?

A

Tranclocation between the long arms of ch9 and 22 resulting in a bcr-abl fusion protein with tyrosine kinase activity. Causes cell to divide uncontrollably. Found in CML and ALL.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What mutations cause abnormal cell proliferation in AML?

A
  • FLT3 mutations
  • Ras mutations
  • Others: c-KIT mutations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What mutations cause blocks in cell differentiation in AML?

A
  • CBF AML (t(8;21) and inv(16))
  • PML-RARα (t(15;17))
  • MLL translocations (11q23)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Which mutation suppresses tumour suppression?

A

NPM1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What can cytogenetics tell you about the prognosis of AML?

A
  • Mutations in NPM1 = good
  • Mutations in FLT3 = bad
  • NPM1+ve/FLT3 ITD-ve gives improved relapse free (61% v 47%) and overall (57% v 23%) survival at 4 years compared with other way round
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is minimal residual disease monitoring and how may it be useful?

A
  • May allow detection of early relapse and allow earlier treatment in some sub-types eg APML
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the poor prognostic factors in ALL?

A
Increasing age
High WCC
Male sex
Certain cytogenetic abnormalities
Poor response to treatment
T-ALL and null-ALL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How is AML managed?

A
  • Induction treatment to obtain remission, then consolidation with further courses of combination chemotherapy
  • In younger patients consider bone marrow transplantation (sibling or MUD)
17
Q

How is ALL managed?

A
  • All patients receive induction chemotherapy, intensive consolidation chemotherapy and prophylaxis of meningeal leukaemia with intrathecal methotrexate and cranial irradiation
  • Following this maintenance chemotherapy is given, or bone marrow transplantation in ‘bad-risk’ patients
18
Q

What is the most serious complication of therapy?

A

All patients with acute leukaemia receiving intensive chemotherapy will become neutropenic for 10 – 21 days

19
Q

What is neutropenic fever?

A

Defined as pyrexia in the presence of a neutrophil count of less than 1.0 x 10^9/l

20
Q

What is neutropenic sepsis?

A
  • Neutropenic patients are in grave danger of developing overwhelming gram negative or gram positive infection
21
Q

How should neutropenic fever be managed?

A
  • Cornerstone of management is immediate administration of broad spectrum IV antibiotics (often Tazocin and Gentamicin) given empirically before the results of cultures are available
22
Q

How can neutropenic sepsis be avoided?

A
  • protective isolation
  • prophylactic antibiotics eg levofloxacin
  • use of granulocyte colony stimulating factors
  • strict hand hygiene